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Abstract
Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is aberrantly expressed in a subset of T cell lymphoma that
commonly affects children and young adults. NPM-ALK possesses significant oncogenic potential that was previously
documented using in vitro and in vivo experimental models. The exact mechanisms by which NPM-ALK induces its
effects are poorly understood. We have recently demonstrated that NPM-ALK is physically associated with type I
insulin-like growth factor receptor (IGF-IR). A positive feedback loop appears to exist between NPM-ALK and IGF-IR
through which these two kinases interact to potentiate their effects. We have also found that a single mutation of the
Tyr644 or Tyr664 residue of the C terminus of NPM-ALK to phenylalanine decreases significantly, but does not com-
pletely abolish, the association between NPM-ALK and IGF-IR. The purpose of this study was to determine whether
the dual mutation of Tyr644 and Tyr664 abrogates the association and interactions between NPM-ALK and IGF-IR. We
also examined the impact of this dual mutation on the oncogenic potential of NPM-ALK. Our results show that NPM-
ALKY644,664F completely lacks association with IGF-IR. Importantly, we found that the dual mutation of Tyr644 and
Tyr664 diminishes the oncogenic effects of NPM-ALK, including its ability to induce anchorage-independent colony
formation and to sustain cellular transformation, proliferation, and migration. Furthermore, the association between
NPM-ALK and IGF-IR through Tyr644 and Tyr664 appears to contribute to maintaining the stability of NPM-ALK protein.
Our results provide novel insights into the mechanisms by which NPM-ALK induces its oncogenic effects through
interactions with IGF-IR in this aggressive lymphoma.
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Introduction
The transmembranous receptor tyrosine kinase anaplastic lymphoma
kinase (ALK) is a member of the insulin receptor family [1]. Members
of this family display structural similarities, including the YXXXYY
motif located within their respective tyrosine kinase domains. The
mechanisms of ALK activation are not completely known. Previous
studies suggested that some of the heparin-binding growth factors
such as midkine and pleiotrophin are capable of binding to and acti-
vating ALK [2–4]. The physiological expression of ALK is seen in
neural tissues at an early stage of human fetal development [5]. There-
after, ALK expression is aberrant and is largely limited to malignant
neoplasms, including an aggressive type of T cell non-Hodgkin lym-
phoma known as anaplastic large-cell lymphoma, which is one of the
most common hematological neoplasms in children and young adults
[6,7]. It is believed that the expression of ALK in this lymphoma is a
secondary event resulting from one of several chromosomal aberrations
that involve the ALK gene on chromosome 2p23 [8,9]. The most
common of these chromosomal aberrations is the t(2;5)(p23;q35)
translocation that, in addition to ALK, involves the nucleophosmin
(NPM ) gene on chromosome 5q35. This translocation leads to the
generation of the chimeric oncogenic tyrosine kinase NPM-ALK [8].
The expression of NPM-ALK is detected in approximately 85% of
ALK-expressing (ALK+) T cell lymphoma cases [6]. Unlike ALK,
NPM-ALK is an entirely intracellular molecule that lacks extracellular
and transmembranous domains. Although NPM-ALK lacks a nuclear
localization signal, it can translocate to the nucleus by forming hetero-
dimers with wild-type (WT) NPM [10].
There is agreement that NPM-ALK plays a crucial role in the
pathogenesis of NPM-ALK+ T cell lymphoma [6,7]. Previous in vitro
studies demonstrated that NPM-ALK promotes cellular survival and
sustains transformation of rodent fibroblasts [11]. Moreover, in vivo
studies in different transgenic mouse models showed that NPM-ALK
initiates and maintains lymphomagenesis [12,13]. Regardless of the
experimental approach, different transgenic mice models demonstrated
that NPM-ALK induces variable types of malignant lymphoma that
included T cell, B cell, and plasma cell neoplasms, which is a striking
difference from the human NPM-ALK+ lymphoma that develops al-
most exclusively in T lymphocytes and is clinicopathologically distinct
from B cell and plasma cell neoplasms. This important observation
implies that, in addition to NPM-ALK, other interacting molecules
are most likely required to develop the immunophenotypic and clinico-
pathologic features that characterize this lymphoma in humans. Pre-
vious studies have documented that survival-promoting molecules,
such as JAK/STAT, AKT/phosphatidylinositol 3-kinase (PI3K), and
mitogen-activated protein (MAP) kinases, are highly expressed and
activated in NPM-ALK+ T cell lymphoma, and it is believed that
NPM-ALK interacts with and activates through phosphorylation these
molecules [14–18]. Nonetheless, our understanding of the mechanisms
by which NPM-ALK induces its oncogenic effects is still evolving.
Type I insulin-like growth factor receptor (IGF-IR) tyrosine kinase is
another member of the insulin receptor family [19]. It has been re-
ported that IGF-IR is expressed in solid tumors, plasma cell myeloma,
and leukemia. It has also been documented that IGF-IR stimulates
cellular survival, promotes metastatic dissemination, and initiates thera-
peutic resistance in these tumors [20–26]. Furthermore, oncogenic
molecules such as EWS–FLI-1, epidermal growth factor receptor,
platelet-derived growth factor receptor (PDGFR), H-ras, and simian
virus 40 large tumor antigen require the contribution of IGF-IR to
induce their cellular oncogenic effects [27–31]. We have recently shown
that IGF-IR is overexpressed and highly phosphorylated/activated
in NPM-ALK+ T cell lymphoma cell lines and primary tumors com-
pared with normal human T lymphocytes that lack the expression of
IGF-IR [32]. Importantly, we used laser scanning electron microscopy
and immunoprecipitation (IP)/Western blot (WB) and found that
NPM-ALK and IGF-IR colocalize and are physically associated, respec-
tively. In addition, our previous results suggested that the two kinases
collaborate to sustain their tyrosine phosphorylation and kinase activa-
tion levels. A single mutation of the Tyr644 or Tyr664 residues, which
are located within the C terminus of NPM-ALK, to phenylalanine
decreased significantly the association between IGF-IR and NPM-
ALK [32]. In the present study, we tested the impact of a dual mutation
of Tyr644 and Tyr664 on the association and interactions between NPM-
ALK and IGF-IR, and we also systematically examined the effects
of this dual mutation on the oncogenic potential of NPM-ALK. Our
data show that the dual mutation of Tyr644 and Tyr664 abrogates com-
pletely the association between NPM-ALK and IGF-IR. Importantly,
we found novel evidence that the association and functional collabora-
tion between NPM-ALK and IGF-IR maintain high levels of phos-
phorylation and tyrosine kinase activity of NPM-ALK, which further
enhance upregulating the phosphorylation of downstream targets. Taken
together, these data support that the interactions between NPM-ALK
and IGF-IR sustain the transformation, proliferation, and migration of
NPM-ALK+ cells.
Materials and Methods
Cell Lines, Cell Cultures, and Treatments
The previously established NPM-ALK+ T cell lymphoma cell
lines Karpas 299, SU-DHL-1, DEL, SUP-M2, and SR-786 (German
Collection of Microorganisms and Cell Culture, Braunschweig, Ger-
many) and the NPM-ALK–negative cell line Mac-2A (a gift from Dr
George Rassidakis, MD Anderson Cancer Center, Houston, TX) were
used [33]. The P6 (mouse BALB/c3T3 fibroblasts overexpressing
human IGF-IR) and R− (mouse 3T3-like fibroblasts with targeted
ablation of Igflr) cell lines were a generous gift from Dr Renato Baserga
(Thomas Jefferson University, Philadelphia, PA) [21,34]. In addition,
the 293T and NIH/3T3 cell lines (American Type Culture Collection,
Manassas, VA) were used in some experiments. Cell lines were main-
tained in RPMI 1640 (T cell lymphoma) or Dulbecco’s modified
Eagle’s medium (P6, R−, 293T, NIH/3T3) supplemented with 10%
fetal bovine serum (FBS; 15% for Mac-2A; Sigma-Aldrich, St Louis,
MO), 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin at 37°C in humidified air with 5% CO2. In some experiments,
NPM-ALK+ T cell lymphoma cell lines were cultured in 1% FBS
overnight and then treated with 500 ng/ml IGF-I (R&D Systems,
Minneapolis, MN).
Picropodophyllin (PPP; Enzo Life Sciences, Farmingdale, NY) or
imatinib mesylate (Enzo Life Sciences) was used to treat P6 cells stably
transfected with NPM-ALK or NPM-ALKY644,664F. Specific targeting
of IGF-IR or phospholipase C–γ (PLC-γ) was achieved using transient
transfection of SMARTpool-designed siRNA. The siCONTROL non-
targeting siRNA was used as a negative control (Dharmacon, Lafayette,
CO). The 293T cell line was transfected using Lipofectamine 2000
(Invitrogen, Grand Island, NY). Electroporation by using the Nucleo-
fector “V” solution was used to transfect all the other cell lines (Amaxa,
Atlanta, GA; A-030 program for NPM-ALK+ lymphoma and Mac-2A
cell lines and T-030 for P6 and R− cell lines).
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Antibodies
Antibodies were obtained from Cell Signaling Technology (Boston,
MA): pIGF-IR (Tyr1131, Catalog No. 3021), pIGF-IR (Tyr1135/1136,
3024), pSTAT3 (Tyr705, 9131) pERK (Thr202/Try201, 9101), pTyr-
100 (9411), PLC-γ (2822), AKT (9272), pAKT (Ser473, 4051),
Hsp70 (4872), Hsp90 (4874), CHIP (2080), pALK (Tyr1586 equivalent
to Tyr646 in pNPM-ALK, 3343), and PDGFRβ (3169); Calbiochem
(Darmstadt, Germany): STAT3 (569388); Dako (Carpinteria, CA):
ALK (M7195); Santa Cruz Biotechnology (Santa Cruz, CA): IGF-IRβ
(sc-9038), ERK (sc-94), and pPDGFRβ (Tyr1021, sc-12909-R); Roche
(South San Francisco, CA): Myc (11667149001); Abcam (Cambridge,
MA): pPLC-γY1235 (ab73993); and Sigma-Aldrich: β-actin (A-2228).
In Situ Proximity Ligation Assay
We used in situ proximity ligation assay (PLA) technique to compare
the physical association between IGF-IR and NPM-ALK versus IGF-IR
and NPM-ALKY644,664F [35]. R− cells were transfected with empty
vector (EV), WT NPM-ALK, or NPM-ALKY644,664F using Lipo-
fectamine 2000 for 48 hours. Cytospin slides were prepared using 10 ×
105 cells and fixed with cold methanol for 5 minutes. Slides were then
washed with phosphate-buffered saline (PBS), fixed with 4% para-
formaldehyde for 20 minutes, permeabilized using 0.1% Triton X-100
in PBS for 20 minutes, and subsequently stained as recommended by
the manufacturer (Olink Bioscience, Uppsala, Sweden). Briefly, slides
were blocked with the blocking solution for 30 minutes at 37°C. The
anti-ALK (354300, mouse; Invitrogen) and anti–IGF-IR (sc-9038,
rabbit; Santa Cruz Biotechnology) antibodies were added simulta-
neously, each at a 1:25 concentration, and the slides were incubated
overnight at 4°C. The slides were then washed, and the anti-mouse and
anti-rabbit PLA probes were added for 1 hour at 37°C. To ligate the two
PLA probes together, the ligation mixture was added for 30 minutes at
37°C. The amplification-polymerase mixture was added for 100 minutes
at 37°C in the dark. Finally, slides were washed and mounted using a
mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI).
Expression Plasmids
Full-length NPM-ALK (amino acids 1–680) in pCDNA3.1(+) was
mutated to generate the NPM-ALKY644F and NPM-ALKY664F con-
structs by using the QuikChange II XL site-directed mutagenesis kit
(200521-5; Stratagene, Santa Clara, CA) according to the manufac-
turer’s instructions [32]. The mutants IGF-IRY950F and IGF-IRK1003A
were generated using a similar approach (primer sequence is shown in
Table 1). To prepare IGF-IR (1–1245) where the C terminus of IGF-IR
was deleted, IGF-IRΔ1245-F-EcoR1 (5′-TAATGAATCAAGGGAATT-
TCGTCGAAT-3′) and IGF-IRΔ1245-R-Not1 (5′-TATATGCGGCC-
GCCCGGSSGCCAGGCTCCAT-3′) were used to amplify portions
of IGF-IR, which were subsequently digested with EcoRJ/Not1, sub-
cloned into pCDNA3.1(+).pCMV-myc-3B vector (Stratagene), and re-
constructed into pCMV-3x-myc vector by using the QuikChange II XL
site-directed mutagenesis kit (200521-5; Stratagene). Then, IGF-IR
and the different IGF-IR mutants were subcloned from pCDNA3.1(+)
(Invitrogen) into the EcoRI and ApaI sites of pCMV-3x-myc vector.
Mutant DNA was sequenced using the ABI 3730xl Genetic Analyzer
(Applied Biosystems, Carlsbad, CA).
Establishment of the P6 and R− Stable Cell Lines That
Permanently Express NPM-ALK or NPM-ALKY644,664F
The lentiviral-based expression vector pLove (Addgene, Cambridge,
MA), the pENTR 3C vector (Invitrogen), and the third-generation
lentivirus packaging vectors pMDLg/pRRE, pRSV-Rev, and pMD2.G
(Addgene) were used to create the stable P6 and R− cell lines. First, we
reconstructed the pENTR 3C vector into p3C–green fluorescent protein
(GFP) using the QuikChange II XL site-directed mutagenesis kit. Then,
NPM-ALK and NPM-ALKY644,664F mutant cDNA were subcloned
into pENTR 3C-GFP vector and then into pLove expression vector
using the Gateway Cloning System (Life Technologies, Grand Island,
NY). For lentiviral production, pLove expression vector was cotrans-
fected with third-generation lentivirus packaging vectors into 293T cells
using Lipofectamine (Invitrogen). Briefly, 293T cells (1 × 106 cells) were
split into 25.0-cm2 flasks 24 hours before transfection, and then the cells
were transfected with 2.5 μg of pLove vector together with 1.875 μg
of the packaging vectors pMDLg and pRSV-Rev and 0.625 μg of the
envelope vector pMD2.G. After 5 hours of incubation at 37°C, fresh
culture medium was added for 48 hours. The lentivirus-containing me-
dium was collected and spun down at 1500 rpm for 5 minutes to pellet
cellular debris, and the supernatant was filtered through 0.45-μm pores.
P6 and R− cells were infected with fresh lentivirus containing medium
supplemented with 8 μg/ml Polybrene (Millipore, Billerica, MA) to
enhance transfection efficiency. Forty-eight to 72 hours after infec-
tion, P6 and R− cells were stably infected with viral particles. Stable
clones were selected by GFP cell sorting through the Becton Dickinson
FACSVantage SE Turbo cell sorter (BD, Franklin Lakes, NJ).
WB and IP
Cell lysates were obtained using standard techniques [the lysis buffer
contained 25 mM Hepes (pH 7.7), 400 mM NaCl, 1.5 mM MgCl2,
2 mM EDTA, 0.5% Triton X-100, 0.1 mM PMSF, 3 mM DTT,
phosphatase inhibitor cocktail (20 mM β-GP, 1 mM Na3VO4; Roche), and
protease inhibitor cocktail (10 μg/ml leupeptin, 2 μg/ml pepstatin,
50 μg/ml antipain, 1× benzamidine, 2 μg/ml aprotinin, 20 μg/ml
chymostatin; Roche)]. For IP, lysates were incubated with primary
antibody overnight at 4°C. Agarose beads conjugated with A/G were
then added and incubated for 2 hours at 4°C. The immunocomplexes
were spun, washed three times with cold PBS and once with lysis
buffer, and then subjected to sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE). For WB, 50 to 80 μg of total protein
was electrophoresed on 8% to 12% SDS-PAGE. The proteins were
transferred to nitrocellulose membranes and probed with specific
primary antibodies and then with the appropriate HRP-conjugated
secondary antibodies (GE Healthcare, Piscataway, NJ). Proteins were
detected using a chemiluminescence-based kit (GE Healthcare).
Glutathione S-Transferase Pull-Down Experiments
Glutathione S -transferase (GST) fusion constructs were expressed
in BL21 Escherichia coli cells, and crude bacterial lysates were prepared
by sonication in 50 mM Tris-HCl (pH 7.4), 1.5 mM EDTA, 1 mM
DTT, 10% (vol/vol) glycerol, and 0.4 M NaCl in the presence of the
Table 1. Primers Used in the Study.
NPM-ALKY644F: F, 5′-CCCTTGTGGGAATGTCAATTTCGGCTACCAGC-3′; R, 5′-AATTG-
ACATTCCCACAAGGGAAGTGACGTA-3′
NPM-ALKY664F: F, 5′-TGCCCTGGAGCATGGTCATTTCGAGGATACCAT-3′; R, 5′-AATGA-
CCAGCTCCAGGGGCAGTAGCGGCTT-3′
IGF-IRY950F: F, 5′-TGCCTCTGTGAACCCGGAGTTCTTCAGCGCTG-3′; R, 5′-AACTCC-
GGGTTCACAGAGGCATACAGCACTC-3′
IGF-IRK1003A: F, 5′-AGAGTGGCCATTGCAACAGTGAACGAGGCC-3′; R, 5′-GGCCTCG-
TTCACTGTTGCAATGGCCACTCT-3′
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protease inhibitor mixture. The in vitro transcription and translation
experiments were performed using rabbit reticulocyte lysate (TNT
Systems; Promega, Madison, WI) and FluroTectTM Greenlys tRNA
labeled according to the manufacturer’s recommendation. In GST pull-
down assays, 10 μg of the appropriate GST fusion protein was mixed
with 30 to 50 μl of the in vitro transcribed/translated products and
incubated in binding buffer (75 mM NaCl, 50 mM Hepes, pH 7.9)
at room temperature for 60 minutes in the presence of the protease
inhibitor mixture. The binding reaction mixture was then added to
30 μl of glutathione-sepharose beads and mixed at 4°C for 2 hours.
The beads were washed three times with binding buffer, resuspended
in 30 μl of 2× SDS-PAGE loading buffer, and resolved on 12%
gels. Then, proteins were detected using a chemiluminescence-based
kit (Promega).
Tyrosine Kinase Activity
The tyrosine kinase activity of IGF-IR was determined after using
NPM-ALK or NPM-ALKY644,664F as a direct substrate by using the
ADP-Glu Kit (Promega). Briefly, IP was used to pull down IGF-IR
protein after transfection of IGF-IR-myc into 293T cells. Coimmuno-
precipitated IGF-IR was incubated with in vitro translated NPM-ALK
or NPM-ALKY644,664F in a buffer containing 150 μM ultra adenosine
triphosphate (ATP), 25mMTris-HCl (pH 7.5), 2 mMDTT, 0.1 mM
Na3VO4, and 10 mM MgCl2 for 1 hour at 37°C. The reaction was
stopped with the ADP-Glu reagent. Thereafter, the luciferase intensity,
by which the IGF-IR kinase activity was quantified, was measured
using the ADP-Glu Luciferase Assay System (Promega).
The tyrosine kinase activity of NPM-ALK and its different mutants
was measured using a commercially available kit (Takara Bio, Otsu,
Shiga, Japan). Cell lysates were prepared and the specific antibody
was used for IP. Agarose beads conjugated with protein A/G were
added. Kinase reactions were initiated by adding ATP-2Na into immo-
bilized wells coated with peptide substrate. Next, HRP-conjugated
anti-phosphotyrosine (PY20) antibody was added to each well and
developed by the addition of HRP and 3,3′,5,5′-tetramethylbenzidine.
The reaction was stopped with 1N H2SO4, and absorbance was mea-
sured at 450 nm in a microplate reader (MRX II; Dynex Technologies,
Chantilly, VA). The ATP-free reaction was used as a negative control.
Confocal Laser Scanning Electron Microscopy
The 293T cells were placed into the cell culture chambers, washed
with PBS, and subjected to fixation/permeabilization in 4% para-
formaldehyde for 20 minutes, followed by 20 minutes in 0.1% Triton
X-100 at room temperature. After blocking with 10% FBS in PBS for
45 minutes, cells were incubated with a mixture of polyclonal rabbit
anti-ALK antibody (Cell Signaling; diluted 1:25 in PBS) and mouse
anti–IGF-IRβ antibody (Invitrogen; diluted 1:100 in PBS) overnight
at 4°C and stained for 90 minutes with a mixture of secondary anti-
bodies, including Alexa Fluor 594 (Catalog No. A21203)–conjugated
donkey anti-mouse IgG (1:300) and Alexa Fluor 488 (A21206)–
conjugated donkey anti-rabbit IgG (1:800; Invitrogen). Images were
visualized by confocal laser scanning microscopy (LSM 510; Carl Zeiss,
Thornwood, NY).
Colony Formation Assay
Colony formation was detected using a cell transformation detec-
tion kit (Chemicon, Billerica, MA). Harvested cells were resuspended
in 0.4% agar in culture medium at a density of 1.25 × 103 cells/
0.25 ml/plate in a 24-well plate and seeded into solidified 0.8% agar
in culture medium. Plates were incubated for 3 to 4 weeks at 37°C in
5% CO2. Fresh culture medium was added one to two times per week.
Colonies were stained and photographed using the FluorChem 8800
Imaging System (Alpha Innotech, Santa Clara, CA).
Cell Migration Assay
Cell migration was studied using 24-well Transwell plates with
polycarbonate membranes (Corning Costar, Cambridge, MA). Briefly,
P6 or R− cells permanently transfected with EV, NPM-ALK, or
NPM-ALKY644,664F were loaded onto the upper compartment. Simul-
taneously, culture medium with 10% FBS was loaded onto the lower
compartment. Plates were incubated for 48 hours at 37°C, and cells
migrating through the membrane into the lower chamber were
counted using light microscopy (Coulter, Miami, FL).
MTT Assay
Cell proliferation was evaluated by using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and a commer-
cially available ELISA-based kit (Promega). Cells were seeded into
96-well plates, a total of 100 μl of an MTT solution was added to each
well, and the cells were then incubated at 37°C and 5% CO2 for
2 hours. Thereafter, cell proliferation was assessed by measuring the
absorbance at 540 nm.
Protein Degradation Assay
Cells were transfected with NPM-ALK plasmids, and NPM-ALK
protein degradation was measured after treatment with cyclohexi-
mide (CHX, c4859; Sigma-Aldrich; 100 μg/ml).
Statistical Analysis
Statistical analysis was performed using a two-tailed Student’s
t test or analysis of variance for repeated measures and Bonferroni
post-hoc test. A P value of <.05 was considered statistically significant.
Results
The Physical Association between NPM-ALK and IGF-IR Is
Tyrosine Phosphorylation Dependent
We previously used laser scanning electron microscopy and IP/
WB experimental approaches and detected cellular colocalization
and physical association between NPM-ALK and IGF-IR, respectively
[32]. In this study, we obtained consistent results using a different ex-
perimental approach, i.e., GST pull-down of recombinant NPM-ALK
and in vitro translated IGF-IR protein (Figure W1). To examine
whether adequate total tyrosine phosphorylation of NPM-ALK and
IGF-IR is a prerequisite for their physical association, we performed
transfection experiments in 293T cells that showed that the associ-
ation between NPM-ALK and IGF-IR was moderately decreased
when the IGF-IRK1003A mutant was used and was markedly de-
creased when the NPM-ALKK210A mutant was used (Figure 1A).
In further support of the necessity of adequate tyrosine phosphor-
ylation, the association between NPM-ALKK210A and IGF-IRK1003A
was almost completely abrogated (Figure 1A). Figure 1B confirms
the lack of tyrosine phosphorylation in the NPM-ALKK210A and
IGF-IRK1003A mutants. Moreover, when Karpas 299 and SU-
DHL-1 cell lines cultured in 1% FBS overnight were stimulated with
IGF-I, the total tyrosine phosphorylation of endogenously expressed
IGF-IR and NPM-ALK was markedly upregulated (Figure 1C ).
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Importantly, this up-regulation was associated with a notable increase
in the association between NPM-ALK and IGF-IR.
Dual Mutation of Tyr644 and Tyr664 in NPM-ALK Abrogates
Its Physical Association with IGF-IR
We previously showed that an individual mutation of the Tyr644 or
Tyr664 residue of NPM-ALK diminishes its association with IGF-IR
[32]. Herein, transfection experiments in 293T cells showed a com-
plete lack of association between IGF-IR and NPM-ALKY644,664F
(Figure 2A). In addition, confocal laser scanning electron microscopy
showed the same cellular colocalization for NPM-ALK and IGF-IR
but not for NPM-ALKY644,664F and IGF-IR (Figure 2B). Our results
were further supported by the in situ PLA, which provided another
evidence that NPM-ALK and IGF-IR are physically associated and
that this association is abolished when Tyr644 and Tyr664 are simulta-
neously mutated to phenylalanine (Figure 2C). Our experiments also
demonstrated that Tyr950 of IGF-IR is the site where it physically
associates with NPM-ALK (Figure W2).
NPM-ALKY644,664F Possesses Significantly Less Potential to
Interact with IGF-IR
To further investigate the effects of dual mutation of Tyr644 and
Tyr664 on the interactions between NPM-ALK and IGF-IR, we per-
formed transfection experiments in R− and P6 cell lines that lack or
express, respectively, the IGF-IR protein (Figure 3A). Compared
with EV, transient transfection of NPM-ALK or NPM-ALKY644,664F
in R− or P6 cells was associated with a modest, albeit statistically sig-
nificant, increase in NPM-ALK tyrosine kinase activity (Figure 3A).
On the contrary, transfection of NPM-ALK into P6 cells was asso-
ciated with a dramatic enhancement of NPM-ALK tyrosine kinase
activity (Figure 3A).
We also generated in vitro translated NPM-ALK and NPM-
ALKY644,664F proteins and compared their effects as direct substrates
on IGF-IR tyrosine kinase activity. In vitro incubation of IGF-IR and
NPM-ALK was associated with a significantly higher level of IGF-IR
tyrosine kinase activity compared with the incubation of IGF-IR
and NPM-ALKY644,664F (Figure 3B).
Next, we further analyzed the interactions between IGF-IR and
NPM-ALKY644,664F compared with other NPM-ALK mutants that
are known to possess inherent functional defects. In this regard,
we used the NPM-ALK (98–680) mutant that lacks NPM and the
ability to form homodimers and the NPM-ALK (98–566) mutant that,
in addition to lacking NPM, also lacks the C terminus that binds with
downstream targets. Our results showed that cotransfection of NPM-
ALK with IGF-IR into 293T cells induced much higher tyrosine ac-
tivity of NPM-ALK than EV cotransfected with NPM-ALK. Notably,
Figure 1. Tyrosine phosphorylation is a prerequisite for the physical association between NPM-ALK and IGF-IR. (A) Transfection studies
in 293T cells followed by IP using anti–c-Myc (the label for transfected IGF-IR) and WB using anti-ALK antibody show that WT NPM-ALK
and WT IGF-IR are physically associated. Whereas a moderate decrease in the association between WT NPM-ALK and IGF-IRK1003A was
noted, a large decrease in the association between WT IGF-IR and NPM-ALKK210A was detected. Importantly, the association between
NPM-ALKK210A and IGF-IRK1003A was almost completely abrogated. Control experiment where anti-ALK antibody was used for IP and WB
is shown. (B) Total tyrosine phosphorylation of the NPM-ALKK210A and IGF-IRK1003A mutants was dramatically reduced compared with
tyrosine phosphorylation of WT NPM-ALK and IGF-IR, respectively. Control experiments where anti-ALK or anti–c-Myc antibodies were
used for IP and WB are shown. (C) IGF-I increased the total tyrosine phosphorylation of endogenous IGF-IR and NPM-ALK in serum-
deprived Karpas 299 and SU-DHL-1 cell lines. The increase in tyrosine-phosphorylated IGF-IR and NPM-ALK was associated with a dra-
matic enhancement of their association.
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Figure 2. Tyr644 and Tyr664 of NPM-ALK are the sites of its association with IGF-IR. (A) IP, using anti–IGF-IR antibody, and WB, using anti-
ALK antibody, were performed in 293T cells transfected with WT NPM-ALK or NPM-ALKY644,664F. The association between WT NPM-ALK
and IGF-IRwas abrogatedwhen Tyr644 and Tyr664 were simultaneouslymutated to phenylalanine. Control experimentwhere IP andWBwere
performed using anti–IGF-IR antibody is shown. In addition, control WB showing the expression of NPM-ALK and IGF-IR was concurrently
performed on cell lysates from Karpas 299 cells. In addition, a negative control where only beads were used is depicted. (B) Laser scanning
electron microscopy shows the expression of transfectedWT NPM-ALK or NPM-ALKY644,664F (red) and IGF-IR (green) proteins in 293T cells.
Bright yellow signals (white arrows) were detected in cells transfected with WT NPM-ALK and IGF-IR (red/green and DAPI/red/green over-
laps). Conversely, these signals were not detected in cells transfected with NPM-ALKY644,664F and IGF-IR. (C) In situ PLA performed in
R− cells shows that transfected WT NPM-ALK associates with transfected IGF-IR. The association between the two proteins is shown
as speckled red signals confined to the cytoplasm and absent in the nucleus. The red signals were not seen in R− cells simultaneously
transfected with NPM-ALKY644,664F and IGF-IR, indicating lack of association of the two proteins. Control experiment where the cells were
transfected with EV is shown.
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Figure 3. NPM-ALKY644,664F demonstrates significantly decreased interactions with IGF-IR. (A) Transfection of WT NPM-ALK or NPM-
ALKY644,664F in R− cells that lack expression of IGF-IR was associated with a relatively small but statistically significant increase in
NPM-ALK tyrosine kinase activity. Similarly, there was a slight increase in tyrosine kinase activity when NPM-ALKY644,664F was trans-
fected into P6 cells that express IGF-IR. Notably, NPM-ALK tyrosine kinase activity was much more pronounced when WT NPM-ALK was
transfected into P6 cells. The results are shown as means ± SE of three different experiments (*P < .05, **P < .01). (B) Measur-
ing IGF-IR tyrosine kinase activity by using in vitro translated WT NPM-ALK or NPM-ALKY644,664F as a direct substrate of IGF-IR shows
that IGF-IR tyrosine kinase activity significantly increased compared to the baseline level only when WT NPM-ALK was used as a sub-
strate. IGF-IR tyrosine kinase activity is depicted as luciferase activity (in relative light unit). The results are shown as means ± SE of
three experiments (*P < .05 compared with other experimental conditions). (C) Transfection of WT NPM-ALK or different functionally
defective constructs with IGF-IR in 293T cells showed that WT NPM-ALK possesses significantly greater tyrosine kinase activity
when transfected with IGF-IR compared to WT NPM-ALK transfected with EV or compared to NPM-ALKY644,664F, NPM-ALK (98–680),
or NPM-ALK (98–566) transfected with IGF-IR. The tyrosine kinase activity of NPM-ALKY644,664F transfected with IGF-IR was similar to WT
NPM-ALK transfected with EV and higher than that of the mutants NPM-ALK (98–680) and NPM-ALK (98–566) transfected with IGF-IR.
The results are shown as means ± SE of three experiments (*P < .01 versus all other experimental conditions, †P< .01 versus all except
NPM-ALK (98–566) + IGF-IR, §P < .01 versus all except EV + EV). (D) Transfection of WT NPM-ALK and IGF-IR into 293T cells was
associated with a significantly higher anchorage-independent colony formation potential when compared with all other conditions.
Transfection of EV and WT NPM-ALK or of IGF-IR and NPM-ALKY644,664F or NPM-ALK (98–680) resulted in a significantly higher number
of colonies than transfection of EV only or of IGF-IR and NPM-ALK (98–566). The results are shown as means ± SE of three experiments
(*P < .01 versus all other experimental conditions). (E) The expression levels of IGF-IR and the different NPM-ALK constructs in 293T cells
after transfection. β-Actin demonstrates equal loading of the different proteins.
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NPM-ALKY644,664F demonstrated significantly reduced tyrosine activity,
compared with NPM-ALK, when cotransfected with IGF-IR (Fig-
ure 3C). Nonetheless, the tyrosine activity of NPM-ALKY644,664F was
still higher than the tyrosine activity of the NPM-ALK (98–680) and
NPM-ALK (98–566) mutants cotransfected with IGF-IR.
In addition, cotransfection of NPM-ALK and IGF-IR into 293T
cells, compared with cotransfection of NPM-ALK with EV or any
of the NPM-ALK mutants with IGF-IR, significantly increased the
anchorage-independent colony formation potential of the cells grown
for 3 to 4 weeks (Figure 3D). Cotransfection of NPM-ALKY644,664F
with IGF-IR was associated with a colony formation potential similar
to that of cotransfection of NPM-ALK with EV or to cotransfection of
NPM-ALK (98–680) with IGF-IR but significantly higher than that
of NPM-ALK (98–566) cotransfected with IGF-IR (Figure 3D). Levels
of expression of the constructs transfected into 293T cells are shown
in Figure 3E .
Dual Mutation of Tyr644 and Tyr664 Diminishes the
Oncogenic Potential of NPM-ALK
Next, we studied the oncogenic potential of the NPM-ALKY644,664F
mutant. We used P6 and R− cells that express or lack IGF-IR,
respectively, to generate clones that stably express NPM-ALK or
Figure 4. Oncogenic defects of NPM-ALKY644,664F. (A) Stable expression of WT NPM-ALK in P6 cells that express considerable levels of
IGF-IR was associated with a remarkable increase in the anchorage-independent colony formation potential of these cells. In contrast, the
potential of P6 cells permanently transfected with NPM-ALKY644,664F to form colonies was comparable to that of P6 cells transfected with
EV (upper panel). The results are shown as means ± SE of three consistent experiments (*P < .0001 versus EV and NPM-ALKY644,664F).
Examples of the P6 cell colonies grown in soft agar are shown (left lower panel). In contrast, R− cells stably transfected with NPM-ALK did
not demonstrate evidence of anchorage-independent colony formation and were similar to the R− cells stably transfected with EV or NPM-
ALKY644,664F (lower left panel). The expression levels of WT NPM-ALK, NPM-ALKY644,664F, and β-actin in P6 and R− cells are illustrated.
A vertical line has been inserted to indicate repositioned gel lanes. Transfection of EV did not induce protein expression (data not shown).
(B) P6 cells permanently transfected with WT NPM-ALK demonstrate remarkably increased migration potential compared to P6 cells trans-
fected with EV or NPM-ALKY644,664F. Notably, R− cells stably transfected with NPM-ALK or NPM-ALKY644,664F failed to undergo cellular
migration. The results are shown as means ± SE of three experiments (*P < .0001 versus EV and NPM-ALKY644,664F in P6 cells). (C) P6
cells permanently transfected with WT NPM-ALK demonstrated morphologic features consistent with transformation including three-
dimensional clumping and polyhedral cellular morphology. Conversely, P6 cells transfected with NPM-ALKY644,664F maintained the spindle-
shape morphology and the monolayer growth pattern characteristic of cells transfected with EV (upper panel). R− cells transfected with
NP-ALK did not show evidence of cellular transformation and were similar to R− cells transfected with EV or with NPM-ALKY644,664F (lower
panel). (D) Transient transfection of WT NPM-ALK, but not NPM-ALKY644,664F, induced a significant increase in the proliferation of the
ALK-negative T cell lymphoma cell line Mac-2A. The expression levels of WT NPM-ALK and NPM-ALKY644,664F in Mac-2A cells are shown
in the left lower panel. WB shown in the right lower panel demonstrated that Mac-2A cells express endogenous IGF-IR. Karpas 299 and
R− cells were used as positive and negative controls, respectively, for the expression of IGF-IR. β-Actin demonstrates equal loading of the
different proteins. A vertical line has been inserted to indicate repositioned gel lanes. The results represent the means ± SE of three con-
sistent experiments (*P < .05 versus EV, **P < .01 versus EV and NPM-ALKY644,664F).
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NPM-ALKY644,664F. There was a notable increase in the anchorage-
independent colony formation potential of P6 cells permanently
transfected with NPM-ALK, but P6 cells transfected with NPM-
ALKY644,664F demonstrated a colony formation potential similar to
that of P6 cells transfected with EV (Figure 4A). Importantly, simi-
lar to R− cells stably transfected with EV or NPM-ALKY644,664F,
R− cells stably transfected with NPM-ALK failed to develop anchorage-
independent colonies (Figure 4A). Levels of expression of NPM-ALK
and NPM-ALKY644,664F in P6 and R− cells are shown in Figure 4A.
Furthermore, whereas NPM-ALK significantly increased the migra-
tion of P6 cells, NPM-ALKY644,664F failed to induce a similar effect
(Figure 4B). However, stable transfection of NPM-ALK failed to
stimulate the migration of R− cells, and its effect was similar to
EV and NPM-ALKY644,664F (Figure 4B). We also noted differ-
ences in the morphologic growth pattern of P6 cells that were per-
manently transfected with NPM-ALK versus those transfected with
NPM-ALKY644,664F (Figure 4C ). NPM-ALK induced morphologic
changes consistent with cellular transformation, which included three-
dimensional clumping, with irregular and polyhedral cellular mor-
phology. In contrast, NPM-ALKY644,664F induced monolayer growth
pattern and spindle-shape cellular morphology that were similar to
control cells transfected with EV. Similar to its effects on colony forma-
tion and cellular migration, NPM-ALK could not induce noticeable
changes in the monolayer growth pattern and spindle shape of R− cells.
The effects of stably transfected NPM-ALK on R− cells were similar to
the effects of EV and NPM-ALKY644,664F (Figure 4C ). We also used
an ALK-negative T cell lymphoma cell line, Mac-2A, that express
endogenous IGF-IR to further examine the contribution of Tyr644
and Tyr664 to the oncogenic potential of NPM-ALK. Transfection
of NPM-ALK significantly increased the proliferation of Mac-2A
cells, but this effect was not present when NPM-ALKY644,664F was
transfected instead (Figure 4D).
Biochemical Consequences of the Dual Mutation of
Tyr644 and Tyr664 in NPM-ALK
To understand the functional defects of lack of association and inter-
actions between NPM-ALK and IGF-IR, we examined the biochemical
changes induced by the NPM-ALKY644,664F mutant. Transfection
of IGF-IR with NPM-ALK or NPM-ALKY644,664F was performed
in 293T cells. Total tyrosine phosphorylation of NPM-ALKY644,664F
was markedly diminished compared with total phosphorylation of
NPM-ALK (Figure 5A). Notably, transfection of NPM-ALKY644,664F
was also associated with a dramatic decrease in total tyrosine phos-
phorylation of IGF-IR (Figure 5A). In addition, the phosphorylation
of Tyr646, which is also located within the C terminus of NPM-ALK,
was diminished when NPM-ALKY644,664F was transfected instead of
NPM-ALK (Figure 5B). Another important observation was that the
phosphorylation of NPM-ALK/IGF-IR common downstream targets,
including STAT3, AKT, and ERK, was remarkably decreased when
NPM-ALKY644,664F was transfected instead of NPM-ALK (Figure 5B).
Dual Mutation of Tyr644 and Tyr664 Decreases NPM-ALK
Protein Stability
It was previously demonstrated that the expression of NPM-ALK
protein can be regulated by the proteasome degradation pathway
[36,37]. A screening experiment using MG132 to inhibit proteasome
degradation in R− cells transfected with NPM-ALKY644,664F also showed
that this mutant is most likely regulated by the protein degradation
pathway (Figure W3). Thereafter, the effects of the dual mutation of
Figure 5. Biochemical alterations resulting from dual mutation of Tyr644 and Tyr664 in NPM-ALK. (A) Cotransfection of IGF-IR and WT
NPM-ALK in 293T cells shows that the two kinases possess high levels of total tyrosine phosphorylation, whereas cotransfection of IGF-IR
and NPM-ALKY644,664F shows that not only NPM-ALKY644,664F but also IGF-IR demonstrate much less total tyrosine phosphorylation levels.
The expressions of IGF-IR and NPM-ALK constructs in 293T cells are shown. (B) Transfection of NPM-ALKY644,664F was associated with
a pronounced decrease in pNPM-ALKY646, pIGF-IRY1131/Y1135, pSTAT3Y705, pAKTS473, and pERKT202/Y204 levels. β-Actin supports equal
protein loading.
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Tyr644 and Tyr664 that causes lack of binding with IGF-IR on the stabil-
ity of NPM-ALK protein were studied. P6 and R− cells were transfected
with NPM-ALK or NPM-ALKY644,664F and then treated with CHX
to inhibit new protein synthesis. There was no change in NPM-ALK
protein levels at 24 hours after treatment of P6 cells (Figure 6A, upper
panel ). In contrast, NPM-ALKY644,664F was less stable in P6 cells,
and its levels decreased at 24 hours after treatment. Importantly, these
findings were more prominent when R− cells were used (Figure 6A,
upper panel ). Densitometry of the WB bands and extrapolation of the
NPM-ALK-to-β-actin ratio showed that, compared to no change in
P6 cells, NPM-ALK decreased to approximately 89% of its baseline level
in R− cells (Figure 6A, lower panel ). In addition, NPM-ALKY644,664F
decreased to 79% and 66% of its baseline levels in P6 and R− cells,
respectively (Figure 6A, lower panel ). To further analyze these
observations, we examined the association between NPM-ALK and NPM-
ALKY644,664F with proteins known to regulate the stability of NPM-
ALK protein [36,38]. Compared withNPM-ALK, NPM-ALKY644,664F
maintained the ability to associate with Hsp70 and CHIP and dem-
onstrated a remarkably reduced ability to associate with Hsp90 (Fig-
ure 6B). Thereafter, we set to directly examine whether the association
between NPM-ALK and IGF-IR, independently from Hsp90, con-
tributes to maintaining the stability of NPM-ALK protein. Specific
down-regulation of IGF-IR by siRNA was associated with a marked
decrease in NPM-ALK protein levels in SUP-M2, SR-786, and
Karpas 299 cell lines (Figure 6C).
Effects of Specific Down-Regulation of PLC-γ on the
Proliferation of NPM-ALK+ T Cell Lymphoma Cells
We have identified Tyr664 as a site that partially associates with
IGF-IR. Because previous studies have shown that Tyr664 of NPM-
ALK is the site of its association with PLC-γ, and also suggested that
this association is required by NPM-ALK to induce mitogenic effects
[39], we set to test the direct effect of the down-regulation of PLC-γ on
NPM-ALK+ T cell lymphoma cells. Specific down-regulation of PLC-γ
by siRNA (Figure W4A, upper panel ) neither decreased the proliferation
of Karpas 299 and DEL cells (FigureW4A, lower panel ) nor reduced the
phosphorylation of STAT3, AKT, and ERK in these cells (FigureW4B).
Expression Levels of IGF-IR and pIGF-IR in the
Mouse Fibroblast NIH/3T3 Cells
Earlier studies have commonly used rodent fibroblasts to examine
the oncogenic effects of exogenously expressed NPM-ALK. How-
ever, the similarities between the biologic backgrounds in rodent
fibroblasts and the lymphoma cells are questionable. Because we have
observed that NPM-ALK+ T cell lymphoma cell lines and primary
human tumors overexpress IGF-IR and pIGF-IR, we were curious
to analyze the endogenous levels of expression of these proteins in
the mouse fibroblast NIH/3T3 cells. WB demonstrated that NIH/
3T3 cells express low levels of IGF-IR protein and lack the expression
of pIGF-IR (Figure W5).
Effect of Selective Inhibition of IGF-IR and PDGFRβ on
NPM-ALK and NPM-ALKY644,664F–Expressing P6 Cells
A recent study demonstrated that PDGFR supports the survival of
NPM-ALK+ T cell lymphoma [40]. WB analysis showed that PDGFR
and pPDGFRY1021 are expressed in P6 cells stably transfected with
NPM-ALK or NPM-ALKY644,664F (Figure W6). Thereafter, we set
to test the effects of targeting IGF-IR by using PPP versus targeting
PDGFR by using imatinib mesylate on the proliferation of P6 cells.
Compared to PDGFR inhibition, inhibition of IGF-IR induced a
slightly more pronounced decrease in the proliferation of the two types
of P6 cells. In addition, combining PPP and imatinib mesylate
induced effects almost similar to the effects of PPP alone (Figure W6).
Discussion
We have previously used laser scanning electron microscopy and IP/
WB and found that NPM-ALK and IGF-IR are physically associated
[32]. Herein, we further demonstrated the physical association between
NPM-ALK and IGF-IR by using two other experimental approaches:
in situ PLA and GST pull-down of recombinant NPM-ALK and
in vitro translated IGF-IR protein. Both approaches consistently sup-
ported the association between the two proteins. Furthermore, we
identified the Tyr950 residue of IGF-IR as the major site where its
association with NPM-ALK occurs. It has been previously shown
that IGF-IR uses Tyr950 for its physical association with the down-
stream modulators IRS-1 and Shc [41–43]. Notably, IRS-1 and Shc
also associate with NPM-ALK [11].
Thereafter, we aimed at performing a systematic analysis of the
association between NPM-ALK and IGF-IR and defining the func-
tional implications of this association. In this regard, we first examined
whether adequate tyrosine phosphorylation of NPM-ALK and IGF-IR
is a prerequisite for their association. It has been previously documented
that NPM-ALK and IGF-IR with functional kinase domains demon-
strate high levels of total tyrosine phosphorylation [10,44,45]. It has
also been shown that the total tyrosine phosphorylation and the func-
tional integrity of the kinase domains are largely dependent on single
lysine residues located within the ATP-binding domains, namely
Lys210 in NPM-ALK and Lys1003 in IGF-IR. Mutations of these lysine
residues to other amino acids such as arginine or alanine resulted in
defected mutants with markedly reduced total tyrosine phosphoryla-
tion [32,46,47]. Cotransfection of IGF-IRK1003A and NPM-ALK in
293T cells modestly decreased their association. However, the associa-
tion between NPM-ALKK210A and IGF-IR was significantly dimin-
ished. More importantly, when NPM-ALKK210A and IGF-IRK1003A
were cotransfected, the association between NPM-ALK and IGF-IR
was completely abrogated. In another approach, we used NPM-ALK+
T cell lymphoma cell lines to examine the effect of the phosphor-
ylation levels of endogenously expressed NPM-ALK and IGF-IR on
their physical association. Stimulation of serum-deprived Karpas 299
and SU-DHL-1 cells with IGF-I increased the total tyrosine phos-
phorylation of IGF-IR and NPM-ALK, which remarkably enhanced
their association. Collectively, these results underscore that adequate
total tyrosine phosphorylation is necessary for the association between
NPM-ALK and IGF-IR. Similar to these findings, it was previously
shown that adequate levels of total tyrosine phosphorylation are re-
quired for NPM-ALK and IGF-IR to physically associate with other
signaling partners [48,49].
Our previous studies using segment deletion mutants suggested
that the C terminus of NPM-ALK is the site of its association with
IGF-IR [32]. Indeed, a mutation of Tyr644 or Tyr664 but not Tyr567
or Tyr646 that are all located within the C terminus of NPM-ALK to
phenylalanine significantly decreased the association of NPM-ALK with
IGF-IR [32]. To further examine the contribution of the Tyr644 and
Tyr664 residues of NPM-ALK to its association with IGF-IR, we
exploited three different strategies—IP/WB, laser scanning electron
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Figure 6. NPM-ALKY644,664F is a less stable protein than WT NPM-ALK. (A) Although treatment of P6 cells that express IGF-IR with CHX did
not induce a notable decrease in transiently transfected WT NPM-ALK levels at 24 hours, CHX decreased NPM-ALKY644,664F levels in these
cells (upper panel). These effects were more pronounced when the R− cells that lack IGF-IR were treated with CHX. Densitometry of the
WB bands was performed and the NPM-ALK-to-β-actin ratio is shown (lower panel). Treatment of P6 cells by CHX induced no changes in
WT NPM-ALK and modestly decreased its levels in R− cells to 89% of the baseline levels. The effect of CHX on NPM-ALKY644,664F was
more pronounced, as it decreased its level to 79% and 66% of the baseline levels in P6 and R− cells, respectively. (B) Transfection studies
in 293T cells showed that WT NPM-ALK associates with Hsp70, Hsp90, and CHIP proteins. Whereas NPM-ALKY644,664F maintained the
association with Hsp70 and CHIP, its association with Hsp90 was markedly decreased compared with WT NPM-ALK. (C) Specific down-
regulation of IGF-IR by siRNA was associated with a remarkable decrease in NPM-ALK protein levels in three different NPM-ALK+ T cell
lymphoma cell lines including SUP-M2, SR-786, and Karpas 299 (upper panel). Densitometric analysis of the ratios between IGF-IR and
β-actin and NPM-ALK and β-actin bands are shown (lower panel).
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microscopy, and in situ PLA—which all failed to show an association
between IGF-IR and NPM-ALKY644,664F. It is important to mention
that these experiments were performed in two different types of cells:
293T cells, where the association with endogenously expressed IGF-IR
was examined, and R− cells, where the association with forcibly expressed
exogenous IGF-IR was analyzed.
Next, the functional interplay between IGF-IR and NPM-ALK or
NPM-ALKY644,664F was studied in P6 cells that overexpress IGF-IR
and compared with that in R− cells with targeted ablation of IGF-IR
[21,34]. A relatively modest, yet statistically significant, increase in
NPM-ALK tyrosine kinase activity was observed when NPM-ALK
was transfected into R− cells and also when NPM-ALKY644,664F was
transfected into P6 or R− cells. Like NPM-ALK, NPM-ALKY644,664F
contains the first 117 amino acids of the N terminus of NPM, which
have been implicated in the homodimerization and subsequent auto-
activation of NPM-ALK [10]. Therefore, the increase in NPM-ALK
tyrosine kinase activity most likely resulted from the inherent abil-
ity of NPM-ALK or NPM-ALKY644,664F to dimerize. Nonetheless,
NPM-ALK tyrosine kinase activity was dramatically increased when
it was transfected into P6 cells. In further support of functional collab-
orations between NPM-ALK and IGF-IR, the tyrosine kinase activity
of IGF-IR significantly increased when in vitro translated NPM-ALK
protein, but not NPM-ALKY644,664F, was used as a direct substrate of
IGF-IR. These data suggest that the presence of IGF-IR and its asso-
ciation with NPM-ALK can reciprocally enhance the basal levels of
their tyrosine kinase activities.
Next, we compared the interactions between IGF-IR and NPM-ALK
or NPM-ALKY644,664F with its interactions with other NPM-ALK
mutants that harbor specific functional defects. Cotransfection of
IGF-IR and NPM-ALKY644,664F in 293T cells did not affect the basal
levels of NPM-ALK tyrosine kinase activity as it induced effects similar
to cotransfection of EV with NPM-ALK. As with the findings discussed
above, these results could be explained by the ability of NPM-ALK or
NPM-ALKY644,664F to form homodimers that possess basal levels of
autoactivated tyrosine kinase. Compared with cotransfection of IGF-IR
and NPM-ALK, which was associated with dramatic enhancement
of NPM-ALK tyrosine kinase activity, transfection of IGF-IR with
the functionally defective mutant NPM-ALK (98–680), which lacks
NPM and the ability to form dimers, was associated with lessened
NPM-ALK tyrosine kinase activity. Finally, transfection of IGF-IR with
the most defective mutant, NPM-ALK (98–566), was associated with
the smallest level of NPM-ALK tyrosine kinase activity. NPM-ALK
(98–566) lacks NPM and the distal 114 amino acid residues of the
C terminus that contain the sites where NPM-ALK physically associates
with Shc, Grb2, PLC-γ, and IGF-IR, and possibly other unidentified
molecules [11,32,39,50].
In addition to its effects on NPM-ALK tyrosine kinase activity, the
collaborative interplay between NPM-ALK and IGF-IR also enhances
the cellular transformation potential of NPM-ALK because cotransfec-
tion of IGF-IR and NPM-ALK significantly increased the anchorage-
independent colony formation of 293T cells. In contrast, transfection
of NPM-ALK alone or IGF-IR with NPM-ALKY644,664F or with
NPM-ALK (98–680) induced lesser effects. As expected, cotransfect-
ing IGF-IR and NPM-ALK (98–566) was associated with the least
number of 293T cell colonies.
When the biologic characteristics of the different clones of stably
transfected P6 cells were assessed, the potential of P6 cells that ex-
pressed NPM-ALKY644,664F to form anchorage-independent colonies
in soft agar or to migrate was much less pronounced than that of P6
cells that expressed NPM-ALK. Moreover, only P6 cells that expressed
NPM-ALK demonstrated morphologic features consistent with cel-
lular transformation. In a striking difference, NPM-ALK failed to
induce anchorage-independent colony formation, migration, or cellu-
lar transformation when stably expressed in R− cells that lack IGF-IR
expression.
In addition to the mouse fibroblast P6 cells, we also compared the
effects of NPM-ALK and NPM-ALKY644,664F using the NPM-ALK–
negative T cell anaplastic large-cell lymphoma cell line Mac-2A, which
expresses endogenous IGF-IR. Transient transfection of NPM-ALK
increased the proliferation of Mac-2A cells, but NPM-ALKY644,664F
failed to induce similar effects. Collectively, these results indicate that
Tyr644 and Tyr664 are required for NPM-ALK to associate and col-
laborate with IGF-IR, and such collaboration potentiates the survival-
promoting and cellular transformation potential of NPM-ALK.
WT NPM is a ubiquitously expressed RNA-binding phospho-
protein [51]. Its physiological functions include the shuttling of ribonu-
cleoproteins between the nucleolus and cytoplasm. The first 117 amino
acids ofNPMcomprise the proximal portion of theN terminus ofNPM-
ALK, but they lack the nuclear localization signal of NPM. Nevertheless,
NPM-ALK forms dimers with WT NPM, and the NPM/NPM-ALK
heterodimer can translocate to the nucleus. In addition, earlier studies
have demonstrated that NPM-ALK can also form homodimers through
the NPM domain, which subsequently induces autoactivation of the
ALK tyrosine kinase domain. This process is believed to be a major
mechanism by which NPM-ALK induces its deregulated signaling
[10]. Whether constitutive activation through homodimerization is the
sole mechanism that leads to NPM-ALK phosphorylation/activation
and whether constitutively active NPM-ALK can induce cellular trans-
formation independently from other interacting molecules remain the
subjects of debate [49,52].
The conclusions of some of the earlier studies could have been
affected by their experimental conditions. Notably, the majority of
these studies were performed using exogenous NPM-ALK that was
forcibly expressed in rodent fibroblasts, e.g., mouse NIH/3T3 or rat-1
fibroblasts. It is possible that the phenotypic backgrounds of these cells
are not ideal for drawing definitive conclusions related to the biologic
characteristics of NPM-ALK. For example, in contrast to the NPM-
ALK+ T cell lymphoma cell lines and primary tumor cells that express
high levels of IGF-IR and pIGF-IR [32], we found that NIH/3T3
cells express low levels of IGF-IR and lack the expression of pIGF-IR.
It is still possible, however, that NPM-ALK induced cellular trans-
formation of rodent fibroblasts such as NIH/3T3 cells through recipro-
cal interaction/activation of endogenously expressed IGF-IR, albeit
at low levels, in these cells. Nonetheless, when we used R− cells that lack
the expression of IGF-IR, NPM-ALK failed to induce cellular trans-
formation. In the work presented herein, a plethora of variable cell
lines, including mouse fibroblasts with different levels of expression of
IGF-IR, human embryonic kidney cells, and NPM-ALK–negative
and NPM-ALK+ T cell lymphoma cell lines, were used with consistent
results.
The relevant observation that modulations of FBS levels through
supplementation, withdrawal, or deprivation can affect the growth
pattern of NPM-ALK+ cells in culture argues against the idea that
the survival of these cells is contingent upon homodimerized and con-
stitutively activated NPM-ALK independent from interactions with
other extracellular or intracellular molecules that might also affect
the phosphorylation and tyrosine kinase activation levels of NPM-
ALK. In line with this concept, we previously found that specific
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down-regulation of NPM-ALK by ALK siRNA was associated with de-
creased levels of pSTAT3 and pAKT in NPM-ALK+ T cell lymphoma
cells [32]. However, the decrease in pSTAT3 and pAKT was largely
recovered when the cells were simultaneously treated with ALK siRNA
and IGF-I, which is known to be present in FBS [53]. These results
suggest that important survival proteins could be activated through
alternative pathways that are complementary to NPM-ALK. In the
current study, we additionally found that extracellular stimulation of
serum-deprived NPM-ALK+ cells by IGF-I not only enhances total
tyrosine phosphorylation of IGF-IR but also increases total tyrosine
phosphorylation of NPM-ALK. Because NPM-ALK lacks extracellular
and transmembranous domains, the effects of IGF-I on NPM-ALK
were most likely mediated through stimulation of IGF-IR by IGF-I.
These observations strongly suggest that extracellular mediators could
interact with intermediary molecules that subsequently affect the basal
levels of the phosphorylation and constitutive tyrosine kinase activation
of NPM-ALK.
In further support of the contribution of other molecules to the
activation and oncogenic effects of NPM-ALK, recent studies demon-
strated that constitutively activated NPM-ALK was only capable of
promoting cellular immortalization and that interactions with H-ras
were required for NPM-ALK to induce cellular transformation [52].
In another study, the Src kinase pp60c-src was found to be physically
associated with NPM-ALK. Importantly, pp60c-src appeared to use
NPM-ALK as a substrate and to significantly increase its tyrosine phos-
phorylation levels [49]. In a similar model, Src kinases were found
to induce phosphorylation of Bcr-Abl and to modulate its cellular
transformation activity [54]. In addition, Src kinases induced phos-
phorylation of IGF-IR at tyrosine residues known to undergo auto-
phosphorylation [55].
To understand the basis underlying the biologic defects resulting
from lack of association and interactions between NPM-ALK and
IGF-IR, we analyzed the biochemical consequences of dual mutation
of NPM-ALK’s Tyr644 and Tyr664 to phenylalanine. This dual muta-
tion was associated with a marked decrease in the total tyrosine phos-
phorylation of NPM-ALK and IGF-IR, providing additional evidence
that the effective association and interplay between these two kinases
can sustain ample levels of total tyrosine phosphorylation. In further
support of this notion, transfection of NPM-ALKY644,664F into 293T
cells was associated with reduced phosphorylation of Tyr646, one of the
four tyrosine residues located within the C terminus of NPM-ALK.
Furthermore, transfection of NPM-ALKY644,664F was associated with
decreased phosphorylation of IGF-IR at Tyr1131 and Tyr1135, which
comprise the first and second tyrosine residues, respectively, of the
YXXXYY motif of the IGF-IR kinase domain. These findings are quite
significant, considering that Tyr1131 and Tyr1135 are used by IGF-IR
to induce cellular transformation [56,57]. Transfection of NPM-
ALKY644,664F was also associated with significant down-regulation
of pSTAT3Y750, pAKTS473, and pERKT202/Y204. These oncogenic
proteins contribute significantly to the signaling of both NPM-ALK
and IGF-IR [14–18,58–62].
Because the treatment of R− cells transfected with NPM-
ALKY644,664F with MG132 induced a marked increase in the levels
of this double mutant, we postulated that NPM-ALKY644,664F is regu-
lated posttranslationally by the proteasome degradation system, which
is also a proposed mechanism for the regulation of NPM-ALK expres-
sion [36,37]. Using CHX to abort new protein formation, we noticed
no changes in the stability of NPM-ALK protein transfected into P6
cells. Conversely, NPM-ALK demonstrated lesser stability when trans-
fected into R− cells. These results suggest that the association between
IGF-IR and NPM-ALK may lead to stabilization of NPM-ALK pro-
tein. Indeed, the stability of NPM-ALKY644,664F was notably decreased
in P6 cells compared with the stability of NPM-ALK in the same cells.
Because the stability of NPM-ALKY644,664F was lower than that of
NPM-ALK in R− cells, we assumed that the association between
NPM-ALK and IGF-IR through Tyr644 and Tyr664 may also involve
other proteins that sustain the stability of NPM-ALK. Previous studies
have shown that the proteasome degradation pathway proteins, in-
cluding Hsp90, Hsp70, and CHIP, associate with and regulate the
stabilization/degradation of NPM-ALK [36,38]. These studies demon-
strated that the association of NPM-ALK with the chaperon Hsp90
enhances the stability of NPM-ALK protein. In contrast, the asso-
ciation with Hsp70 facilitates its degradation, and this process is
accelerated by the CHIP ligase [36]. In this study, we found that
NPM-ALKY644,664F retained the ability to associate with Hsp70 and
CHIP, but its ability to associate with Hsp90 was greatly diminished,
which could explain, at least partially, the decreased stability of this
mutant compared with NPM-ALK. Thereafter, we questioned whether,
in addition to Hsp90, IGF-IR also supports the stability of NPM-ALK
protein. Specific targeting of IGF-IR by siRNA was associated with
a remarkable down-regulation of NPM-ALK protein levels in NPM-
ALK+ T cell lymphoma cells. These novel data suggest that the presence
Figure 7. Our data propose a novel model in which NPM-ALK
and IGF-IR are physically associated through Tyr644 and Tyr664 of
NPM-ALK and Tyr950 of IGF-IR. Through this association, the phos-
phorylation and tyrosine kinase activity of the two oncogenic pro-
teins aremaintained at high levels, and this leads to the up-regulation
of the phosphorylation of common downstream targets including
STAT3, AKT, and ERK. Such effects enhance the transformation,
proliferation, and migration of NPM-ALK+ T cell lymphoma cells. In
addition, the physical association between NPM-ALK and IGF-IR, in
the presence of Hsp90 (not shown), appears to sustain the stability
of NPM-ALK protein.
Neoplasia Vol. 15, No. 6, 2013 NPM-ALK Oncogenic Effects Facilitated by IGF-IR Shi et al. 681
of Hsp90 and IGF-IR in the same protein complex with NPM-ALK
contributes to maintaining the stability of NPM-ALK.
The NPM-ALK protein contains 12 tyrosine residues (www.
phosphosite.org), and some of these residues are used for associations
and interactions with other proteins. The tyrosine residues that asso-
ciate NPM-ALK with IRS-1, Vav3, pp60c-src, and Shc have been iden-
tified as Tyr156, Tyr343, Tyr418, and Tyr567, respectively [11,49,63]. In
addition, the Grb2 protein was shown to associate with several amino
acid residues of NPM-ALK including Tyr156 and Tyr567 [50]. Of im-
portant note is that the sites of the association between NPM-ALK and
some of its most important downstream targets such as PI3K/AKT
and STAT3 are not known. In relevance to our findings related to
Tyr664, it was previously reported that PLC-γ contributes to the mito-
genicity of NPM-ALK through its association with Tyr664 [39]. The
conclusion that PLC-γ contributes to the mitogenicity of NPM-ALK
was largely based on two indirect observations: 1) overexpression of
PLC-γ partially rescued Ba/F3 cells transfected with NPM-ALKY664F
from interleukin-3 (IL-3) dependence, and 2) unlike NPM-ALKY664F,
the expression of NPM-ALK enhanced the production of inositol
phosphates in Ba/F3 cells [39]. In our study, specific down-regulation
of PLC-γ by siRNA neither decreased the proliferation of NPM-
ALK+ T cell lymphoma cells nor decreased the expression levels of
pSTAT3Y705, pAKTS473, and pERKT202/Y204. Although a role of
PLC-γ in NPM-ALK+ T cell lymphoma cannot be ruled out, the
exact mechanisms of this role remain to be delineated.
In conclusion, in this work we present novel data showing that
the oncogenic role of NPM-ALK is facilitated through its physical
association and interactions with another oncogenic tyrosine kinase,
namely, IGF-IR. The association with IGF-IR supports high levels of
kinase activity and tyrosine phosphorylation levels of NPM-ALK,
which appears to enhance the phosphorylation of common oncogenic
downstream targets. Our results suggest that the functional interplay
between NPM-ALK and IGF-IR stimulates cellular transformation,
proliferation, and migration; induced by NPM-ALK, as well as hinders
the degradation of NPM-ALK protein (proposed model is depicted in
Figure 7). These findings expand current knowledge of the biology of
NPM-ALK and may lead to improved therapeutic approaches to the
treatment of clinically aggressive NPM-ALK+ T cell lymphoma.
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Figure W1. Physical association between NPM-ALK and IGF-IR.
GST pull-down assay was performed by incubating recombinant
GST–NPM-ALK with in vitro translated IGF-IR. GST pull-down of
the complex was followed by WB using anti–IGF-IR antibody
(upper panel). The bottom left panel shows the recombinant
GST–NPM-ALK (arrowheads). The bottom right panel shows in vitro
translated IGF-IR protein (arrowheads). Luciferase and NPM-ALK
were included as positive controls (arrowheads).
Figure W2. Tyr950 of IGF-IR is the site of its association with NPM-
ALK. Transfection studies in 293T cells showed that the associa-
tion of IGF-IR with NPM-ALK was remarkably decreased when the
Tyr950 residue of IGF-IR was mutated to phenylalanine. The IGF-IR
(1–1250) mutant lacks the C terminus segment. The levels of expres-
sion of NPM-ALK and IGF-IR and its different mutants are illustrated
in the lower panel.
Figure W3. Effect of MG132 on NPM-ALKY644,664F expression.
Treatment of R− cells with MG132 significantly increased the
levels of transfected NPM-ALKY644,664F protein, which suggests
that NPM-ALKY644,664F expression is regulated by the protein deg-
radation pathway. β-Actin shows equal protein loading.
Figure W4. Effects of specific targeting of PLC-γ on NPM-ALK+
T cell lymphoma cells. (A) Specific targeting of PLC-γ by siRNA
decreased its basal levels in Karpas 299 and DEL cell lines, which
was also associated with down-regulation of pPLC-γY1253 (upper
panel). However, treatment with PLC-γ siRNA for up to 96 hours
did not affect the proliferation of Karpas 299 and DEL cells (lower
panel). β-Actin shows equal protein loading. (B) Treatment of DEL
cell line with PLC-γ siRNA did not affect the phosphorylation levels
of STAT3, AKT, or ERK. β-Actin shows equal protein loading. Simi-
lar results were obtained in Karpas 299 cells (data not shown).
Figure W5. Expression of IGF-IR in NIH/3T3 cells. WB showed that
the NIH/3T3 cell line expresses small levels of IGF-IR protein. In
addition, pIGF-IRY1131 is not present in these cells. Lysates from
R− and P6 cells were used as negative and positive controls, re-
spectively, for the expression of IGF-IR/pIGF-IRY1131. β-Actin sup-
ported equal loading of the proteins.
Figure W6. Effects of inhibition of IGF-IR and PDGFRβ on the proliferation of P6 cells stably transfectedwith NPM-ALK or NPM-ALKY644,664F.
PDGFR and pPDGFRY1021 are expressed in P6 cells stably transfected with EV, NPM-ALK, or NPM-ALKY644,664F (upper panel). The expres-
sion of pPDGFRY1021 is higher in P6 cells transfected with NPM-ALKY644,664F, suggesting that increased phosphorylation of PDGFRmight be
due to the lack of association and interactions between NPM-ALK and IGF-IR. NIH/3T3 cells were used as a positive control. At 48 hours,
targeting IGF-IR using PPP, PDGFR using imatinib mesylate or PPP and IGF-IR by combining the two inhibitors induced a concentration-
dependent decrease in the viability of P6 cells transfected with NPM-ALK or NPM-ALKY644,664F (lower panel). However, the two types of P6
cells were more sensitive to the effects of PPP compared with imatinib (PPP: P< .0001 for both NPM-ALK and NPM-ALKY644,664F; imatinib:
P < .001 for NPM-ALK and P = .001 for NPM-ALKY644,664F). In addition, the effects of PPP alone appeared to be almost comparable to the
effects of PPP and imatinib combined together (P = .0003 for NPM-ALK and P = .0002 for NPM-ALKY644,664F). It is possible that these
results were because P6 cells express higher levels of IGF-IR/pIGF-IR than PDGFR/pPDGFR. At low concentrations, P6 cells transfected
with NPM-ALK were more sensitive to the effects of the different treatment regimens than P6 cells transfected with NPM-ALKY644,664F.
At higher concentrations, the two types of P6 cells demonstrated similar responses. Further studies are required to explore these observa-
tions. Normal human T cells were used as a negative control for the effects of PPP and imatinib. The concentrations of PPP and imatinib
used to treat P6 cells were based on previously published data related to these inhibitors in mouse fibroblasts [32,64].
